Trial · NCT01229527
Comparison Between Two Different Dosages of Remifentanil During Colonoscopy
NCT01229527, Phase 4, Completed, Ospedale San Raffaele; results first posted 2012-02-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison Between Two Different Dosages of Remifentanil During Colonoscopy. Trials, record NCT01229527. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01229527
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison Between Two Different Dosages of Remifentanil During Colonoscopy
- NCT number
- NCT01229527
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 90 participants, actual
- Lead sponsor
- Ospedale San Raffaele
- Conditions
- Colonoscopy
- Interventions
- Remifentanil, Remifentanil, Meperidine
- First posted
- 2010-10-27
- Last updated
- 2012-02-01
- Results first posted
- 2012-02-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 | > 0 minutes | Ten key parameters (Activity, Respiration, Circulation, Consciousness, O2 Saturation, Dressing, Pain, Ambulation, Fasting-feeding, Urine Output)are included in the Modified Aldrete Score. The maximum and minimum score for each parameter is respectively 2 and 0. The maximum total score is 20 and patient can be discharged when the total score is ≥18. |
| Secondary | Patient's Satisfaction | After the end of colonoscopy (when patients were completely awake) and 24 h after the procedure via telephone | The degree of satisfaction about the quality of sedation was measured with VAS (Visual Analog Scale) where 0 means no satisfaction and 100 means maximum satisfaction. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 | > 0 minutes | minutes | MEDIAN | |
| SECONDARY | Patient's Satisfaction | After the end of colonoscopy (when patients were completely awake) and 24 h after the procedure via telephone | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 | Remifentanil RS1 | 0 | Inter-Quartile Range 0 to 1 | minutes | |
| Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 | Remifentanil RS2 | 0 | Inter-Quartile Range 0 to 1 | minutes | |
| Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 | Meperidine | 2 | Inter-Quartile Range 1 to 4 | minutes | |
| Patient's Satisfaction | Remifentanil RS1 | 95.87 | Standard Deviation 9.72 | units on a scale | |
| Patient's Satisfaction | Remifentanil RS2 | 93.50 | Standard Deviation 12.40 | units on a scale | |
| Patient's Satisfaction | Meperidine | 96.27 | Standard Deviation 7.62 | units on a scale |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Remifentanil RS1 | 30 | |
| Overall Study | STARTED | Remifentanil RS2 | 30 | |
| Overall Study | STARTED | Meperidine | 30 | |
| Overall Study | COMPLETED | Remifentanil RS1 | 30 | |
| Overall Study | COMPLETED | Remifentanil RS2 | 30 | |
| Overall Study | COMPLETED | Meperidine | 30 | |
| Overall Study | NOT COMPLETED | Remifentanil RS1 | 0 | |
| Overall Study | NOT COMPLETED | Remifentanil RS2 | 0 | |
| Overall Study | NOT COMPLETED | Meperidine | 0 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypotension | Vascular disorders | Remifentanil RS1 | 5 | 30 | |
| other | Hypotension | Vascular disorders | Remifentanil RS2 | 4 | 30 | |
| other | Hypotension | Vascular disorders | Meperidine | 6 | 30 | |
| other | Bradycardia | Cardiac disorders | Remifentanil RS1 | 2 | 30 | |
| other | Bradycardia | Cardiac disorders | Remifentanil RS2 | 1 | 30 | |
| other | Bradycardia | Cardiac disorders | Meperidine | 1 | 30 | |
| other | Desaturation | Respiratory, thoracic and mediastinal disorders | Remifentanil RS1 | 0 | 30 | |
| other | Desaturation | Respiratory, thoracic and mediastinal disorders | Remifentanil RS2 | 3 | 30 | |
| other | Desaturation | Respiratory, thoracic and mediastinal disorders | Meperidine | 1 | 30 | |
| other | Dizziness | Ear and labyrinth disorders | Remifentanil RS1 | 0 | 30 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Remifentanil RS1 | ||
| Total, all-cause mortality | Remifentanil RS2 | ||
| Total, all-cause mortality | Meperidine | ||
| Total, other adverse events | Remifentanil RS1 | 7 | 30 |
| Total, other adverse events | Remifentanil RS2 | 9 | 30 |
| Total, other adverse events | Meperidine | 16 | 30 |
| Total, serious adverse events | Remifentanil RS1 | 0 | 30 |
| Total, serious adverse events | Remifentanil RS2 | 0 | 30 |
| Total, serious adverse events | Meperidine | 0 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01229527
GET https://conductscience.org/api/trials/v1/NCT01229527/events?page=2